trending Market Intelligence /marketintelligence/en/news-insights/trending/ye2thk51dkmvzfzef_zacg2 content esgSubNav
In This List

United Therapeutics settles patent litigation with Watson Laboratories

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


United Therapeutics settles patent litigation with Watson Laboratories

United Therapeutics Corp. agreed to settle a patent litigation with California's Watson Laboratories Inc.

The case involved United Therapeutics' hypertension drug Tyvaso. The Silver Spring, Md.-based company sued Watson Laboratories, which sought to market a generic version of Tyvaso.

Under the settlement, United will allow Watson to market its product starting Jan. 1, 2026. The license only covers the generic version of Tyvaso.

Further, the companies will drop pending litigation over patents related to Watson's abbreviated new drug application for the generic medicine.

The agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice

Watson Laboratories is a privately held unit of Israel's Teva Pharmaceutical Industries Ltd.